Skip to main content
SpringerLink
Log in

Using rHuG-CSF in Multiple Myeloma: Consolidated Data, Evolutions, and New Concepts

  • Chapter
  • First Online:
Twenty Years of G-CSF

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 937 Accesses

Abstract

The major risk of infection in cancer patients is correlated with duration and severity of chemotherapy-induced neutropenia, which depend on several factors, including the underlying disease, patient’s related characteristics, the intensity of chemotherapy, bone marrow reserve, the use of hematopoietic growth factors, and the stem cell dose in case of transplantation [1, 2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. NCCN Clinical Practice Guidelines in Oncology (2010) Myeloid Growth Factors. V.1.2011. http://www.nccn.org

  2. Aapro MS, Bohlius J, Cameron DA, European Organisation for Research and Treatment of Cancer et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32

    Article  PubMed  CAS  Google Scholar 

  3. Renwick W, Pettengell R, Green M (2009) Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs 23:175–186

    Article  PubMed  CAS  Google Scholar 

  4. Keating GM (2011) Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization. Drugs 71:679–707

    Article  PubMed  CAS  Google Scholar 

  5. Morabito F, Gentile M, Mazzone C et al (2010) Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. Eur J Haematol 85:181–191

    Article  PubMed  CAS  Google Scholar 

  6. Musto P, D’Auria F, Pietrantuono G et al (2009) First-line treatment of multiple myeloma in elderly patients: the GIMEMA multiple myeloma working party perspective. Curr Drug Targets 10:906–922

    Article  PubMed  CAS  Google Scholar 

  7. Offidani M, Corvatta L, Morabito F et al (2011) How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. Expert Opin Investig Drugs 20(6):779–793

    Article  PubMed  CAS  Google Scholar 

  8. Palumbo A, Mateos MV, Bringhen S, San Miguel JF (2011) Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 25:181–191

    Article  PubMed  CAS  Google Scholar 

  9. Offidani M, Corvatta L, Polloni C et al (2011) Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leuk Lymphoma 52:776–785

    Article  PubMed  CAS  Google Scholar 

  10. Persona EP, Mesa MG, Sánchez PJ, Rodríguez AP (2011) Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. Adv Ther 28(Suppl 1):11–16

    Article  CAS  Google Scholar 

  11. Ria R, Gasparre T, Mangialardi G et al (2010) Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant 45:277–281

    Article  PubMed  CAS  Google Scholar 

  12. Kuwabara T, Kobayashi S, Sugiyama Y (1996) Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 28:625–658

    Article  PubMed  CAS  Google Scholar 

  13. Hayashi N, Kinoshita H, Yukawa E, Higuchi S (1999) Pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration. J Clin Pharmacol 39:583–592

    Article  PubMed  CAS  Google Scholar 

  14. Carter CR, Whitmore KM, Thorpe R (2004) The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol 75:515–522

    Article  PubMed  CAS  Google Scholar 

  15. Saito T, Usui N, Asai O et al (2007) Elevated serum levels of human matrix metalloproteinase-9 (MMP-9) during the induction of peripheral blood stem cell mobilization by granulocyte colony-stimulating factor (G-CSF). J Infect Chemother 13:426–428

    Article  PubMed  CAS  Google Scholar 

  16. Carion A, Benboubker L, Hérault O et al (2003) Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cells. Br J Haematol 122:918–926

    Article  PubMed  CAS  Google Scholar 

  17. Ataergin S, Arpaci F, Turan M et al (2008) Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 83:644–648

    Article  PubMed  CAS  Google Scholar 

  18. Romeo A, Chierichini A, Spagnoli A et al (2010) Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. Transfusion 50:2432–2446

    Article  PubMed  Google Scholar 

  19. Lefrère F, Bernard M, Audat F et al (1999) Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leuk Lymphoma 35:501–505

    Article  PubMed  Google Scholar 

  20. Kopf B, De Giorgi U, Vertogen B et al (2006) A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 38:407–412

    Article  PubMed  CAS  Google Scholar 

  21. Keating GM (2011) Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 71:1623–1647

    Google Scholar 

  22. Jantunen E (2011) Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opin Biol Ther 11:1241–1248

    Google Scholar 

  23. Putkonen M, Rauhala A, Pelliniemi TT, Remes K (2009) Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. Ann Hematol 88:673–680

    Article  PubMed  Google Scholar 

  24. Hosing C, Qazilbash MH, Kebriaei P et al (2006) Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133:533–537

    Article  PubMed  CAS  Google Scholar 

  25. Steidl U, Fenk R, Bruns I et al (2005) Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 35:33–36

    Article  PubMed  CAS  Google Scholar 

  26. Tricot G, Barlogie B, Zangari M et al (2008) Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica 93:1739–1742

    Article  PubMed  CAS  Google Scholar 

  27. Bruns I, Steidl U, Kronenwett R et al (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:180–185

    Article  PubMed  CAS  Google Scholar 

  28. Musto P, Scalzulli PR, Terruzzi E et al (2007) Peg-filgrastim versus filgrastim after autologous stem cell transplantation: case-control study in patients with multiple myeloma and review of the literature. Leuk Res 31:1487–1493

    Article  PubMed  CAS  Google Scholar 

  29. Samaras P, Blickenstorfer M, Siciliano RD et al (2011) Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann Hematol 90:89–94

    Article  PubMed  CAS  Google Scholar 

  30. Mathew S, Adel N, Rice RD et al (2010) Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant 45:1522–1527

    Article  PubMed  CAS  Google Scholar 

  31. Castagna L, Bramanti S, Levis A et al (2010) Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 21:1482–1485

    Article  PubMed  CAS  Google Scholar 

  32. Gerds A, Fox-Geiman M, Dawravoo K et al (2010) Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 16:678–685

    Article  PubMed  CAS  Google Scholar 

  33. Wannesson L, Luthi F, Zucca E et al (2011) Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls. Leuk Lymphoma 52:436–443

    Article  PubMed  CAS  Google Scholar 

  34. Ferrara F, Izzo T, Criscuolo C et al (2010) Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on an outpatient basis. Hematol Oncol 29:1–5

    Google Scholar 

  35. Ribeiro D, Veldwijk MR, Benner A et al (2007) Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion 47:969–980

    Article  PubMed  CAS  Google Scholar 

  36. Orciuolo E, Buda G, Marturano E et al (2011) Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res 35:899–903

    Article  PubMed  CAS  Google Scholar 

  37. Straka C, Sandherr M, Salwender H et al (2011) Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. Blood 17:2121–2128

    Article  Google Scholar 

  38. Gunzer K, Clarisse B, Lheureux S, Delcambre C, Joly F (2010) Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data. Expert Opin Biol Ther 10:615–630

    Article  PubMed  CAS  Google Scholar 

  39. Aapro M, Crawford J, Kamioner D (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18:529–541

    Article  PubMed  Google Scholar 

  40. Sörgel F, Lerch H, Lauber T (2010) Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs 24:347–357

    Article  PubMed  Google Scholar 

  41. Ferro HH, Juni M, Bello R, Vidal A, Diez RA, Pavlovsky S (2009) Utilization study of filgrastim (Neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients. Transfus Apher Sci 41:87–93

    Article  PubMed  Google Scholar 

  42. Barosi G, Bosi A, Abbracchio MP, et al (2011) Key concepts and critical issues on biosimilars in hematology. A position paper of the Italian Society of hematology, Italian Society of Experimental Hematology, and Italia group for Bone Marrow transplantation. Haematologica 96:937–942

    Google Scholar 

  43. Lefrère F, Brignier AC, Elie C et al (2011) First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther 28:304–310

    Article  PubMed  Google Scholar 

  44. Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russell N (2011) The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 25:1–6

    Article  PubMed  CAS  Google Scholar 

  45. Steinberg M, Silva M (2010) Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin’s lymphoma or multiple myeloma. Clin Ther 32:821–843

    Article  PubMed  CAS  Google Scholar 

  46. DiPersio JF, Stadtmauer EA, Nademanee A et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720–5726

    PubMed  CAS  Google Scholar 

  47. D’Addio A, Curti A, Worel N et al (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 46:356–363

    Article  PubMed  Google Scholar 

  48. Duarte RF, Shaw BE, Marín P et al (2011) Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 46:52–58

    Article  PubMed  CAS  Google Scholar 

  49. Calandra G, McCarty J, McGuirk J et al (2008) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41:331–338

    Article  PubMed  CAS  Google Scholar 

  50. Worel N, Rosskopf K, Neumeister P et al (2011) Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 51:968–975

    Article  PubMed  CAS  Google Scholar 

  51. Basak GW, Jaksic O, Koristek Z, et al (2011) Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol 86:488–495

    Google Scholar 

  52. Dugan MJ, Maziarz RT, Bensinger WI et al (2010) Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin’s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 45:39–47

    Article  PubMed  CAS  Google Scholar 

  53. Attolico I, Pavone V, Ostuni A, et al (2011) Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma. Biol Blood Marrow Transplant. Jul 24. [Epub ahead of print] PMID: 21791194

    Google Scholar 

  54. Giralt S, Stadtmauer EA, Harousseau JL et al (2009) IMWG International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23:1904–1912

    Article  PubMed  CAS  Google Scholar 

  55. Basak GW, Jaksic O, Koristek Z et al (2011) Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol 86(6):488–495

    Article  PubMed  CAS  Google Scholar 

  56. Fruehauf S, Ehninger G, Hübel K et al (2010) Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin’s lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 45:269–275

    Article  PubMed  CAS  Google Scholar 

  57. Tricot G, Cottler-Fox MH, Calandra G (2010) Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 45:63–68

    Article  PubMed  CAS  Google Scholar 

  58. Fruehauf S, Veldwijk MR, Seeger T et al (2009) A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor AMD3100 (plerixafor) mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 11:992–1001

    Article  PubMed  CAS  Google Scholar 

  59. Taubert I, Saffrich R, Zepeda-Moreno A et al (2011) Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Cytotherapy 13:459–466

    Article  PubMed  CAS  Google Scholar 

  60. Bruns I, Steidl U, Fischer JC et al (2008) Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 93:347–355

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Onco-Hematology, Unit of Hematology and Stem Cell Transplantation, IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Via Padre Pio 1, Rionero in Vulture, PZ, 85028, Italy

    Pellegrino Musto

Authors
  1. Pellegrino Musto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pellegrino Musto .

Editor information

Editors and Affiliations

  1. Amgen Inc., One Amgen Center Drive, Thousand Oaks, 91320, California, USA

    Graham Molineux

  2. MA Foote Associates, Par Five Court 4284, Westlake Village, 91362, California, USA

    MaryAnn Foote

  3. Amgen, Inc., One Amgen Center Dr. 1, Thousand Oaks, 91320, California, USA

    Tara Arvedson

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Basel AG

About this chapter

Cite this chapter

Musto, P. (2012). Using rHuG-CSF in Multiple Myeloma: Consolidated Data, Evolutions, and New Concepts. In: Molineux, G., Foote, M., Arvedson, T. (eds) Twenty Years of G-CSF. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0218-5_12

Download citation

Publish with us

Policies and ethics

Search

Navigation